The Biopharmaceutical Corporation has recently updated on Q2 and post period end activities, underlining the recent deals made to expand plasma processing capacity, at relatively little extra cost, thereby paving the way to accelerate the already exciting drug and biopharmaceutical development programme and establish production capacity not only for scale up in clinical work, but also for the near term commercialisation of products likely to come to market.
21 Aug 2015
Ready for the next step
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ready for the next step
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
21 Aug 2015 -
Author:
Derren Nathan -
Pages:
8
The Biopharmaceutical Corporation has recently updated on Q2 and post period end activities, underlining the recent deals made to expand plasma processing capacity, at relatively little extra cost, thereby paving the way to accelerate the already exciting drug and biopharmaceutical development programme and establish production capacity not only for scale up in clinical work, but also for the near term commercialisation of products likely to come to market.